Clinical Trials · NCT04569747
A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer
- Phase
- Phase 2
- Recruitment status
- Active Not Recruiting
- Sponsor
- Dana-Farber Cancer Institute
- Enrollment
- 393
- Start date
- Jan 2021
- Locations
- 32 sites, United States
- Primary endpoint
- Invasive Disease Free Survival at 3 Years